Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
HCoV
SARS-CoV-2
children
cross-immunity
pre-exisiting immunity
respiratory infection
Journal
mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
aheadofprint
Résumé
Numerous clinical parameters link to severe coronavirus disease 2019, but factors that prevent symptomatic disease remain unknown. We investigated the impact of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and endemic human coronavirus (HCoV) antibody responses on symptoms in a longitudinal children cohort (
Identifiants
pubmed: 38270455
doi: 10.1128/mbio.02722-23
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM